SpyGlass Pharma, Inc.

424B4 priced

Price $16.00 · 9,375,000 shares · Gross proceeds $150,000,000

SpyGlass Pharma, Inc. is conducting its initial public offering (IPO) of 9,375,000 shares of common stock at $16.00 per share, totaling $150 million. The company, an emerging growth company, focuses on developing sustained drug delivery solutions for chronic eye conditions, particularly glaucoma. Its lead product, the BIM-IOL System, is designed to reduce intraocular pressure during cataract surgery, with Phase 3 trials initiated in 2025. The filing outlines risks related to clinical trial outcomes, regulatory approvals, and market competition.

CERT inactive

The current filing for SpyGlass Pharma, Inc. appears to be a corrected or amended submission (CERT form) following an earlier effectiveness notice (EFFECT form). However, the content of the current filing is largely inaccessible due to corrupted or encrypted data, limiting insights into specific updates or disclosures.

8-A12B effective

SpyGlass Pharma, Inc. filed Form 8-A12B to register its common stock, $0.00001 par value, for trading on The Nasdaq Stock Market LLC. The filing incorporates by reference the description of the securities from its S-1 Registration Statement (File No. 333-292779), initially filed on January 16, 2026, and amended. The company is transitioning from a previous CERT filing to this registration under Section 12(b) of the Exchange Act.

EFFECT effective

SpyGlass Pharma, Inc. has received effectiveness for its S-1 registration statement, paving the way for its initial public offering (IPO) of 9,375,000 common shares. The offering price is expected to range between $15.00 and $17.00 per share, with the company aiming to list on Nasdaq under the symbol 'SGP.' The IPO is contingent on meeting Nasdaq listing standards. The company's lead product, the BIM-IOL System, demonstrated significant intraocular pressure reduction in clinical trials, with 95% of patients off topical medications at 36 months. SpyGlass is an emerging growth company with a focus on long-acting drug delivery solutions for chronic eye conditions.

S-1/A amended

Price $16.00 · Range $15.00 to $17.00 · 9,375,000 shares

SpyGlass Pharma, Inc. is conducting an initial public offering (IPO) of 9,375,000 shares of common stock, with an expected price range of $15.00 to $17.00 per share. The company, a late-stage biopharmaceutical firm, focuses on developing long-acting drug delivery solutions for chronic eye conditions, particularly glaucoma. Its lead product, the Bimatoprost Drug Pad-IOL System (BIM-IOL System), is in Phase 3 trials, with plans to submit a 505(b)(2) New Drug Application (NDA) to the FDA in 2028. The IPO aims to fund further development, commercialization, and regulatory efforts, with the stock expected to list on Nasdaq under the symbol "SGP."

S-1 filed

SpyGlass Pharma, Inc. is conducting its initial public offering (IPO) to raise capital for the commercialization of its lead product candidate, the Bimatoprost Drug Pad-IOL System (BIM-IOL System), designed to treat elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. The BIM-IOL System, which delivers sustained bimatoprost over three years, is in Phase 3 trials with expected FDA submission in 2028. The company aims to address unmet needs in glaucoma care by integrating IOP-lowering therapy into routine cataract surgery, potentially expanding access beyond MIGS-trained surgeons. The IPO plans to list on Nasdaq under the symbol 'SGP' with an estimated offering price range.

DRS/A amended

SpyGlass Pharma, Inc. is conducting its initial public offering (IPO) for common stock, aiming to list on Nasdaq under the symbol 'SGP.' The company focuses on developing the Bimatoprost Drug Pad-IOL System (BIM-IOL System) for treating chronic eye conditions like glaucoma and ocular hypertension. The BIM-IOL System, designed to deliver sustained bimatoprost over three years during cataract surgery, has shown promising results in clinical trials, including a 37% mean IOP reduction at 36 months. The company has initiated two Phase 3 trials and plans to submit a 505(b)(2) New Drug Application (NDA) to the FDA. The offering includes underwriters Jefferies, Leerink Partners, Citigroup, and Stifel.

DRS filed

SpyGlass Pharma, Inc. is a late-stage biopharmaceutical company developing the Bimatoprost Drug Pad-IOL System (BIM-IOL System) for treating chronic eye conditions, specifically glaucoma and ocular hypertension. The company is preparing for its initial public offering (IPO), aiming to list on Nasdaq under the symbol 'SGP.' The BIM-IOL System, designed to deliver sustained bimatoprost over three years during cataract surgery, is in Phase 3 trials with anticipated FDA submission via the 505(b)(2) pathway. The filing highlights the product's potential to address unmet needs in glaucoma management, including long-term therapeutic durability and reduced reliance on patient adherence to topical medications. The company projects a $13 billion addressable market in the U.S. and emphasizes its emerging growth company status with reduced reporting requirements.